Thermoablation

On July 15, 2025, the Austrian Institute for HTA (AIHTA) published four new HTAs (decision support documents) and two updates to previous decision support documents that provide recommendations regarding possible inclusion of new procedures in the reimbursement catalog of individual medical services (MEL). The assessments concerned cardiovascular, gastrointestinal, interventional radiology, men's health, urology, and orthopedics fields.

In July 2024, the National Institute for Health and Disability Insurance (INAMI-RIZIV) approved a new agreement (Convention) allowing reimbursement for percutaneous CT-guided ablation of renal, hepatic, pulmonary, and bone tumors. The agreement will come into force on November 1, 2024, and will be valid until October 31, 2029.

On July 15, 2024, the Austrian Institute for HTA (AIHTA) published three decision support documents that provide recommendations regarding the inclusion of new medical interventions in the catalog of individual medical services (MEL) for reimbursement, as well as two updates to previous decision support documents. The decisions relate to cardiovascular, peripheral vascular, interventional radiology, neuromodulation, and endocrine technology groups.

On October 20, 2023, the Federal Office of Public Health (FOPH) published six newly initiated health technology assessments, four of which relate to MedTech. These belong to pulmonary, interventional radiology, and physiotherapy technology groups.